{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2015"],"condition":["CARCINOMA COLORETTALE METASTATICO","Colorectal Cancer","Colorectal Neoplasms","Metastatic colorectal cancer","METASTATIC COLORECTAL CANCER"],"disease":["Metastatic Colorectal Cancer","Colorectal Cancer","Colorectal Neoplasms","Carcinoma Colorettale Metastatico"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2178309"],"location":["Cyprus","Egypt","Portugal","Russia","Greece","South Korea","Netherlands","Sweden","Austria","China","Brazil","Poland","Algeria","Slovakia","Slovenia","France","Serbia","Bosnia and Herzegovina","Argentina","United Kingdom","Spain","Turkey","Belgium","Denmark","North Macedonia","Italy","Mexico","Germany"],"study_start_month":["4"],"keyword":["Vemurafenib","Pertuzumab","Capecitabine","Zelboraf 240 mg Film-coated Tablets","Erbitux®","Cetuximab","Trastuzumab","MPDL3280A","Fluorouracil","Atezolizumab","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)","description":"This randomized, multi-center, active-controlled, open-label, parallel-group study will investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line mCRC. Participants with mCRC are eligible for entry and cannot have received any prior chemotherapy in the metastatic setting. The entire study duration is anticipated to be approximately 7.5 years.","dates":{"creation":"2015-04-15"},"accession":"2178309","cross_references":{"ClinicalTrials___gov":["NCT02291289"],"EU Clinical Trials Register":["2014-001017-61"]}}